Related Experiment Video

Updated: May 21, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated

Peng Wang1, Jinpu Yu, Qiang Yin

  • 1Department of Neuro-oncology & Neurosurgery, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Neurochemical Research
|June 19, 2012
PubMed

Insights

Rosiglitazone, a PPAR-γ activator, inhibits growth and induces cell cycle arrest in glioma cells. This anti-glioma effect is mediated by blocking the TGF-beta signaling pathway, offering potential therapeutic strategies.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glioma is a highly malignant central nervous system tumor.
  • Peroxisome proliferator-activated receptor γ (PPAR-γ) activators, like thiazolidinediones (TZDs), show anti-tumor properties.
  • Understanding novel therapeutic targets for glioma is crucial.

Purpose of the Study:

  • To investigate the role and mechanism of rosiglitazone in human glioma cells.
  • To determine if rosiglitazone exhibits anti-proliferative effects on glioma.
  • To elucidate the signaling pathways affected by rosiglitazone in glioma.

Main Methods:

  • Treatment of U87 and U251 human glioma cell lines with rosiglitazone.
  • Assessment of cell proliferation, cell cycle progression, and apoptosis.
  • Analysis of TGF-beta signaling pathway components, including TGF-beta, TGF-betaR2, Smad3 phosphorylation, Smad3/Smad4 complex formation, p21, and c-Myc expression.

Main Results:

  • Rosiglitazone significantly suppressed the growth of U87 and U251 glioma cells.
  • Rosiglitazone induced cell cycle arrest and apoptosis in glioma cells.
  • Rosiglitazone inhibited TGF-beta and TGF-betaR2 expression, Smad3 phosphorylation, and Smad3/Smad4 complex formation.
  • Rosiglitazone modulated the expression of Smad3/Smad4 associated regulators, p21 and c-Myc.

Conclusions:

  • Rosiglitazone demonstrates anti-proliferative and cell cycle-arresting effects on human glioma cells.
  • The anti-tumor activity of rosiglitazone is linked to the inhibition of the TGF-beta signaling pathway.
  • Rosiglitazone represents a potential therapeutic agent for glioma treatment by targeting the TGF-beta pathway.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...